Valneva and Pfizer tout results for the PhII of its Lyme disease vaccine
Pfizer and Valneva are touting positive results in a Phase II trial for their Lyme disease vaccine candidate when it was administered as a booster …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
